Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma …

Introduction To systematically assess the predictive significance of systemic immune-
inflammation index (SII) in renal cell carcinoma (RCC). Methods Relevant studies published …

ABSTRACT Background Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have
been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only …

Objective: Cutaneous metastases of renal cell carcinoma (CMRCC) are rare and associated
with a poor prognosis. The aim of this study is to evaluate the incidence and the prognosis of …

Objectives Renal cell carcinoma (RCC) is the most lethal urologic malignancy with
increasing incidence worldwide. The conventional treatment strategies for advanced or …

The identification of new prognostic markers of renal cell carcinoma (RCC) is an urgent
problem in oncourology. To investigate the potential prognostic significance of tumor …

Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC)
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …

Introduction: Prognostic nutritional index (PNI) was indicted as a potential prognostic
biomarker for cancer. However, the conclusion remains uncertain for renal cell carcinoma …

Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal
cell carcinoma whose pathogenesis is not well understood. We aimed at identifying novel …

Abstract Background Hepatitis C virus (HCV) interferes with activation of innate and adaptive
immune responses. Theoretically, the efficacy and toxicity of immune checkpoint inhibitors in …